The evolution of therapeutic modalities drives the adoption of single-use technologies.
FDA Approves New Influenza Vaccine Manufactured with Novel Technology
January 18th 2013FDA has approved Protein Sciences's FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human flu vaccine. FDA approved Flublok for people 18–49 years old.